Skip to main content
European Commission logo print header

A highly accurate breast cancer diagnostic test for effective personalized treatment and assessment of therapy response.

Descrizione del progetto

Un nuovo test per la diagnosi del cancro al seno per il trattamento personalizzato

Il cancro al seno (BC) è il cancro più comune nelle donne di tutto il mondo, ma i test attuali per la diagnosi non sono precisi, spesso conducendo a diagnosi errata e trattamento inesatto. L’obiettivo del progetto Multiplex8+, finanziato dall’UE, consiste nello sviluppo di un test personalizzato e preciso per la diagnosi di BC in fase iniziale e avanzata. Il test combina due tecnologie multiplexate brevettate di diagnosi del cancro: la visualizzazione (ibridazione fluorescente in sito dell’RNA, RNA FISH) e il sequenziamento dell’RNA. La combinazione di queste tecnologie contribuirà ad eliminare la diagnosi errata e consentirà un sistema specifico di codice a barre per il BC, al fine di suggerire un trattamento personalizzato particolare e valutarne durata e valore prognostico. La fase attuale del progetto comporta lo stabilimento di un laboratorio accreditato per la convalida clinica, seguito dalla creazione della prima azienda di biotecnologie ad alto valore in Slovacchia.

Obiettivo

Breast cancer (BCa) is the most common cancer in women worldwide with 2.1M new cases diagnosed annually, and this number is expected to double in 2030. However, today’s diagnostic tests lack precision and, as a result, many BCa patients are misdiagnosed then treated inaccurately, putting their lives at risk while creating undue problems for families and healthcare systems. MultiplexDX (a leading Slovak biotechnology company) proposes a personalized and precise diagnostic test for early and late stage BCa called Multiplex8+. The test combines two IP-protected, revolutionary and multiplexed cancer diagnostic technologies, visualization (RNA FISH) and RNA sequencing. By combining the two technologies to eliminate misdiagnosis, Multiplex8+ defines a specific BCa barcode that suggests a specific personalized treatment, length of therapy and clarifies how likely will a BCa patient benefit from chemotherapy or not.

There are 2 main objectives of this project: 1. Establish an ISO-15189 accredited laboratory to provide diagnostic services to cancer centers (B2B) and additionally to patients (B2C). A clinical validation on 4 000 tissue samples will be conducted to obtain clinically-based evidence; 2. Build the first successful high-value biotech company in Slovakia. The company has already raised €2,05M in seed investments and grants and started sales of subproducts generating €300k in revenues since 2016. MultiplexDX is operating in the Comenius University Science Park in Bratislava and consists of 17 team members, 5 business and 7 scientific advisors. Our planned accumulated revenues in the first 5 years are €305,3M, generating a net profit of €133,0M and representing a ROI of 10,3. Importantly, Multiplex8+ is supported by the entire oncology value chain (patient associations, cancer centers, hospitals, KOLs, insurance companies, pharma/medtech, clinical laboratories, biobanks, investors, etc.).

Invito a presentare proposte

H2020-EIC-SMEInst-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-EIC-SMEInst-2018-2020-3

Meccanismo di finanziamento

SME-2 - SME instrument phase 2
æ

Coordinatore

MULTIPLEXDX S.R.O.
Contribution nette de l'UE
€ 2 449 527,50
Indirizzo
Ilkovicova 8
841 04 Bratislava
Slovacchia

Mostra sulla mappa

PMI

L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.

Regione
Slovensko Bratislavský kraj Bratislavský kraj
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Altri finanziamenti
€ 1 049 797,50